Jasper Hellweg
Stock Analyst at Argus Research
(2.72)
# 2,022
Out of 4,911 analysts
87
Total ratings
50.7%
Success rate
17.49%
Average return
Main Sectors:
Stocks Rated by Jasper Hellweg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Downgrades: Hold | n/a | $131.52 | - | 4 | Apr 4, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $360 → $400 | $304.50 | +31.36% | 7 | Oct 31, 2024 | |
| ILMN Illumina | Upgrades: Buy | $150 | $109.30 | +37.24% | 7 | Aug 28, 2024 | |
| SNY Sanofi | Maintains: Buy | $55 → $60 | $50.37 | +19.12% | 2 | Jul 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,060 → $1,170 | $563.26 | +107.72% | 9 | Jun 25, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $465 → $550 | $469.65 | +17.11% | 7 | Jun 17, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $80 → $85 | $72.66 | +16.98% | 3 | May 30, 2024 | |
| NVO Novo Nordisk | Maintains: Buy | $115 → $125 | $71.70 | +74.34% | 1 | Feb 1, 2024 | |
| MRNA Moderna | Maintains: Buy | $160 → $140 | $34.15 | +309.96% | 4 | Sep 13, 2023 | |
| ABBV AbbVie | Downgrades: Hold | n/a | $190.28 | - | 2 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $200 | $152.12 | +31.48% | 6 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $16.54 | - | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $290 | $199.17 | +45.60% | 4 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $100 | $108.51 | -7.84% | 3 | Jun 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $270 → $295 | $264.96 | +11.34% | 4 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $7.17 | - | 3 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $135 | $168.55 | -19.91% | 5 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $29.22 | - | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $28.43 | - | 2 | Apr 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $246.26 | - | 3 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $45.70 | - | 4 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $155 | $334.32 | -53.64% | 3 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $142.03 | -36.63% | 1 | Sep 19, 2018 |
Biogen
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $131.52
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $360 → $400
Current: $304.50
Upside: +31.36%
Illumina
Aug 28, 2024
Upgrades: Buy
Price Target: $150
Current: $109.30
Upside: +37.24%
Sanofi
Jul 26, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $50.37
Upside: +19.12%
Regeneron Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $1,060 → $1,170
Current: $563.26
Upside: +107.72%
Vertex Pharmaceuticals
Jun 17, 2024
Maintains: Buy
Price Target: $465 → $550
Current: $469.65
Upside: +17.11%
AstraZeneca
May 30, 2024
Maintains: Buy
Price Target: $80 → $85
Current: $72.66
Upside: +16.98%
Novo Nordisk
Feb 1, 2024
Maintains: Buy
Price Target: $115 → $125
Current: $71.70
Upside: +74.34%
Moderna
Sep 13, 2023
Maintains: Buy
Price Target: $160 → $140
Current: $34.15
Upside: +309.96%
AbbVie
Apr 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $190.28
Upside: -
Jun 17, 2022
Maintains: Buy
Price Target: $225 → $200
Current: $152.12
Upside: +31.48%
Jan 27, 2022
Downgrades: Hold
Price Target: n/a
Current: $16.54
Upside: -
Sep 10, 2021
Maintains: Buy
Price Target: $260 → $290
Current: $199.17
Upside: +45.60%
Jun 9, 2021
Upgrades: Buy
Price Target: $100
Current: $108.51
Upside: -7.84%
May 20, 2021
Maintains: Buy
Price Target: $270 → $295
Current: $264.96
Upside: +11.34%
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $7.17
Upside: -
Oct 21, 2020
Upgrades: Buy
Price Target: $135
Current: $168.55
Upside: -19.91%
Sep 4, 2020
Downgrades: Hold
Price Target: n/a
Current: $29.22
Upside: -
Apr 17, 2020
Downgrades: Hold
Price Target: n/a
Current: $28.43
Upside: -
Apr 6, 2020
Downgrades: Hold
Price Target: n/a
Current: $246.26
Upside: -
Oct 30, 2019
Downgrades: Hold
Price Target: n/a
Current: $45.70
Upside: -
Nov 6, 2018
Maintains: Buy
Price Target: $150 → $155
Current: $334.32
Upside: -53.64%
Sep 19, 2018
Maintains: Buy
Price Target: $85 → $90
Current: $142.03
Upside: -36.63%